Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 27, 2010

Merck KGaA Partners with European ScreeningPort on Multiple Sclerosis Research

  • European ScreeningPort entered into an agreement with Merck KGaA to aid in drug discovery for multiple sclerosis. The firm will establish a high-throughput screening (HTS) assay for a target implicated in the disease.

    European ScreeningPort will evaluate a variety of biochemical and cellular assay formats. Ultimately, it is envisaged that an appropriate HTS assay will be developed that can be employed in a small molecule screening campaign to identify starting points for drug discovery.

    European ScreeningPort is a public-private-partnership offering fee-for-service small molecule screening to academic institutions. It aims to provide a link in Europe between academic research and the pharmaceutical industry.

    Its deal with Merck was inked as part of the New Drugs Fighting Neurological Diseases Consortium (NEU²). It also includes Bionamics, Evotec, and the University Medical Center Hamburg-Eppendorf. The NEU² consortium focuses on the development of novel therapies against neurological diseases with a specific focus on multiple sclerosis. Efforts are coordinated by Bionamics, an independent project management company and founder of NEU².



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »